Innosphere takes on new firm, while another graduates

FORT COLLINS — As one new startup is joining the Fort Collins-based Innosphere incubator program, another is graduating.

SunTech Drive LLC, a solar-power electronics company, is joining Innosphere’s Scaleup Program. The program is tailored to helping established companies navigate the challenges of growing a business in key areas like raising capital, exit planning and talent acquisition. Boulder-based SunTech Drive’s products blend solar and AC grid power to offset grid power consumption and eliminate peak-demand charges to the consumer.

“It’s an exciting time at SunTech Drive and our ability to capitalize on our early success is further bolstered by partnering with Innosphere,” John LoPorto, CEO of SunTech Drive, said in a prepared statement. “SunTech was merely an idea just five years ago, and now we’re poised to grow into a major player in the power electronics and energy IoT markets. By leveraging Innosphere’s scaling expertise and networks, we feel confident in our evolution and are extremely excited to start writing the next chapter of our story.”

SPONSORED CONTENT

Federal District Court Rules Corporate Transparency Act Unconstitutional . . . But Most Small Businesses Must Still Comply

Lyons Gaddis Real Estate and Business Attorney Cameron Grant shares important details of the Corporate Transparency Act (CTA).

Meanwhile, Denver-based Immunocept Medical Products is graduating from Innosphere after meeting its goal of a successful acquisition. CytoPherx, a San Diego-based company, has acquired Immunocept Medical Products. The combined company is rebranding to SeaStar Medical. The two companies are working on medical devices for patients with acute kidney injuries.

“Both companies coming together strengthens IP protection with the combined patent portfolios,” Chris Jaynes, chief commercialization officer of SeaStar Medical and former CEO of Immunocept, said in a prepared statement. “Combined, there are 62 issued and pending U.S. patents covering nearly everything that can be done with hollow fiber membranes in the acute inflammation and multiorgan failure therapeutic space. Our technologies greatly improve efficiencies and lower costs of manufacturing.”